Recursion Pharmaceuticals Inc. stocks have been trading up by 15.41 percent amid heightened optimism over its AI-driven drug discovery progress.
Click Here for a Millionaire's POV on Trading RXRX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Extended Tempus AI partnership now runs through 2029/11, shifting to $42M in committed license payments over three years from up to $84M in discretionary fees over two years.
- New economics give Recursion’s TxFM RNA foundation model a non‑exclusive, worldwide license footprint via Tempus AI.
- RXRX gained about 2.6% after the revised Tempus AI agreement hit the tape.
- Recent Form 4 filings show insider ownership changes in RXRX but lack detail on size, price, or trade direction.
Live Update At 12:34:41 EDT: On Monday, October 05, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 15.41%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
RXRX has been acting like a classic high‑beta biotech with a story traders care about. Over the last few weeks, Recursion Pharmaceuticals has pushed from the low $3s to the mid‑$4s, with the latest daily close near $4.76 after hitting an intraday high of $4.83. That’s a strong percentage move off the 3.14–3.20 base seen in mid‑September.
On the fundamentals, RXRX is still a heavy cash‑burn AI‑driven drug discovery play. Quarterly revenue runs around $7.3M, but losses are steep, with recent net income at about -$131M and EBITDA at roughly -$113M. Margins are deep in the red, and return metrics like return on equity and return on assets are sharply negative. In plain English, Recursion Pharmaceuticals is spending heavily to build its platform.
More Breaking News
- PURR Stock Extends Rally As Buyers Crowd Into Hyperliquid Strategies
- BBD Stock Climbs As Banco Bradesco Insiders Load Up Shares
- MTSI Stock Rebounds As Analysts Back AI And Defense Story
- Synaptics SYNA Soars As Onsemi Ups All-Cash Buyout
The balance sheet, however, is why traders keep giving RXRX room. The company holds about $545.7M in cash and short‑term investments, against limited debt and a current ratio near 5. That runway matters. It gives Recursion Pharmaceuticals time to monetize its AI models and partnerships, which is exactly why headline deals like Tempus AI move the stock.
Why Traders Are Watching RXRX Right Now
The latest Tempus AI news is exactly the kind of catalyst momentum traders hunt. Recursion Pharmaceuticals extended its data license partnership with Tempus to 2029/11 and reshaped the economics around RXRX’s platform. Instead of chasing up to $84M in discretionary payments over two years, RXRX locked in $42M of committed license payments over three years. That swap takes some theoretical upside off the table but replaces it with real, contracted cash flow.
For traders, that predictability matters more than a big hypothetical number that may never fully show up. RXRX is still burning over $100M in free cash flow per quarter, so having $42M scheduled over three years helps smooth expectations and support that cash pile. It doesn’t fix the burn, but it turns a lumpy revenue line into something easier to model.
The other key piece is validation. Recursion Pharmaceuticals granted Tempus a non‑exclusive, worldwide license to its proprietary RNA foundation model TxFM. Tempus agreeing to license TxFM this way signals RXRX’s AI models have commercial value, not just slide‑deck buzz. That’s why the market reaction was positive: RXRX stock popped about 2.6% after the deal went public.
On the tape, the intraday chart shows steady accumulation. RXRX opened around $4.16, briefly dipped toward $4.06, then trended higher almost all day to close near the highs at $4.76. Pullbacks were shallow and bought quickly, a pattern active traders love when a fresh news story is driving the move.
Meanwhile, several Form 4 filings flagged insider or major shareholder ownership changes in RXRX. But with no detail on whether they were buys, sells, or grants, those filings are just background noise next to the Tempus AI catalyst.
Conclusion
RXRX is a classic story‑driven biotech, but the latest Tempus AI extension gives that story a bit more structure. Recursion Pharmaceuticals now has $42M in committed license payments lined up over the next three years, directly tied to its TxFM RNA foundation model. That helps offset a brutal profit profile in the near term and buys more time for the pipeline and platform to mature.
For short‑term traders, the 2.6% pop and strong intraday trend show that the market liked the trade‑off: less theoretical upside, more real money. The recent run from the low $3s to the high $4s puts RXRX back on breakout watch, especially if volume stays elevated and the stock keeps holding higher lows. At the same time, the financials remind everyone this is still a high‑risk, high‑reward name powered by cash reserves and partnerships, not profits.
The Form 4 activity around RXRX is worth tracking but, without clear direction or size, it doesn’t change the core trading thesis right now. The main driver is still how Recursion Pharmaceuticals executes on deals like Tempus and proves its AI drug‑discovery engine can generate durable revenue. This is where trading discipline really matters: As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” RXRX fits that approach well, because sizing, entries, and risk levels around catalysts like Tempus can matter more than trying to nail every cent of the move.
As Tim Sykes likes to say, “The market doesn’t care about your opinion, only about price action and catalysts.” RXRX now has both—a concrete Tempus AI catalyst and a chart that’s waking up. This article is for educational and research purposes only and is not investment advice; traders still need to do their own homework, manage risk, and cut losses fast.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.